Publication: DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
Loading...
Identifiers
Date
2019-10-19
Authors
Hidalgo-Tenorio, Carmen
Vinuesa, David
Plata, Antonio
Martin-Davila, Pilar
Iftimie, Simona
Sequera, Sergio
Loeches, Belen
Lopez-Cortes, Luis Eduardo
Fariñas, Mari Carmen
Fernandez-Roldan, Concepcion
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
Abstract
To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.
Description
MeSH Terms
Aged
Anti-Bacterial Agents
Cost-Benefit Analysis
Drug-Related Side Effects and Adverse Reactions
Endocarditis, Bacterial
Female
Gram-Positive Bacterial Infections
Humans
Length of Stay
Male
Middle Aged
Retrospective Studies
Sepsis
Teicoplanin
Treatment Outcome
Anti-Bacterial Agents
Cost-Benefit Analysis
Drug-Related Side Effects and Adverse Reactions
Endocarditis, Bacterial
Female
Gram-Positive Bacterial Infections
Humans
Length of Stay
Male
Middle Aged
Retrospective Studies
Sepsis
Teicoplanin
Treatment Outcome
DeCS Terms
Tiempo de Internación
Dosificación
Antibacterianos
Sepsis
Endocarditis
Curación en Homeopatía
Dosificación
Antibacterianos
Sepsis
Endocarditis
Curación en Homeopatía
CIE Terms
Keywords
Bloodstream infection, Dalbavancin, Endocarditis
Citation
Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019 Oct 19;18(1):30